Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Researchers have identified three biomarkers that signify an increased risk of death or requirement for lung transplantation in patients with pulmonary arterial hypertension.
The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology.
The Australian Scleroderma Interest Group has derived a screening algorithm for pulmonary arterial hypertension in patients with systemic sclerosis that saves costs by reducing the need for transthoracic echocardiography and right heart catheterisation.
The 6-minute walk distance of patients with systemic sclerosis-associated pulmonary arterial hypertension is not a suitable marker for tracking treatment-related haemodynamic changes, say researchers.
The genetic architecture of a debilitating and potentially fatal vascular disease has for the first time been detailed in its entirety, providing clinicians with the comprehensive data needed to improve diagnosis and deliver more personalised patient care.
"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.
Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
Two members of the vascular endothelial growth factor family are highly specific and moderately sensitive for the presence of pulmonary hypertension, report researchers.
Upfront treatment with the combination of ambrisentan and tadalafil improves outcomes in patients with pulmonary arterial hypertension more than either treatment as monotherapy, shows a randomised trial.
Patients with connective tissue disease-associated pulmonary arterial hypertension have a poorer response to advanced PAH treatments than those with idiopathic disease, finds a meta-analysis.
A novel treatment algorithm for pulmonary arterial hypertension is launched today in new pulmonary hypertension guidelines from the European Society of Cardiology and European Respiratory Society.
A physical therapy researcher with the IU School of Health and Rehabilitation Services at Indiana University-Purdue University Indianapolis has been awarded a $465,000 National Institutes of Health grant to optimize aerobic exercise training for patients with pulmonary arterial hypertension, a goal data suggests could reduce morbidity and mortality among those with the disease.
Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015.
Researchers have identified a molecular pathway by which downregulation of microRNA-126 contributes to right ventricular failure in patients with pulmonary arterial hypertension.
Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators.
Anticentromere and isolated nucleolar autoantibodies are prevalent in systemic sclerosis patients with pulmonary arterial hypertension, but they do not predict survival, US research shows.
Cardiome Pharma Corp. today reported financial results for the second quarter and six months ended June 30, 2015. Amounts, unless specified otherwise, are expressed in U.S. dollars and in accordance with generally accepted accounting principles used in the United States of America (U.S. GAAP).
Cardiome Pharma Corp. today announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to support regulatory approval in China. The study will be conducted in healthy volunteers.
Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.